TSXV/AQS (TSXV/AQS)

TSX Venture Exchange: TSXV/AQS · CAD

CA$0.01

+0.00 (0.0%)· Recorded snapshot

Market cap	663.2K
Revenue (ttm)	918.5K
Net income (ttm)	-656.3K
EPS (ttm)	-CA$0.00
Shares out	132.6M
Volume	0
Beta	-0.29

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 918.5K
Net income (ttm): -656.3K
EPS (ttm): -CA$0.00
Market cap: 663.2K

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 11P50 16.8P75 23.9

Trailing P/En/a

P25 9.9P50 23.3P75 38.5

ROEn/a

P25 -104.1P50 -30P75 6.7

ROICn/a

P25 -55.9P50 -12.1P75 5

Benchmarks · 1M

All TSXV/AQS indicators

Market & fundamental data

Available fields

156

Groups with data

Currency

CAD

Showing 156 of 156 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CAD
Country	Canada
Country code	CA
Earnings date	2026-09-11
Employees change	-2
Employees growth	-14.29%
Enterprise value	CAD 7.2M
Exchange	TSX Venture Exchange
Financial currency	CAD
Financial report date	2025-09-30
First seen	2026-07-12
Fiscal year end	December
Founded	2013
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
ISIN number	CA0076361033
Last refreshed	2026-10-29
Market cap	CAD 663,172
Price	CAD 0.01
Price currency	CAD
Sector	Healthcare
SIC code	2834
Stock price date	2025-04-25
Symbol	tsxv/AQS
Website	https://www.aequuspharma.ca

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-98.96%
EV/Sales	7.87x
FCF / EV yield	-1.6%
FCF yield	-17.47%
Industry forward P/E	34.38x
P/S ratio	0.72x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-62.5%
Gross margin	56.95%
Operating margin	-62.5%
Pretax margin	-71.46%
Profit margin	-71.46%
ROA	-68.07%
ROA (5Y)	-73.69%
ROCE	8.33%
SBC / revenue	-1.84%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	8
EPS growth years	2
Gross profit growth	136.85%
Gross profit growth (Q)	75.06%
Gross profit growth 3Y	-33.57%
Gross profit growth 5Y	-25.49%
Net income growth quarters	8
Net income growth years	2
Revenue growth	122.3%
Revenue growth (Q)	69.74%
Revenue growth (QoQ)	15.37%
Revenue growth 3Y	-20.9%
Revenue growth 5Y	-16.6%
Revenue growth quarters	6
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	CAD 165,410
EBIT	CAD -574,039
EPS	CAD -0.00
FCF per share	CAD -0.00
Financing cash flow	CAD 59,442
Free cash flow	CAD -115,840
Free cash flow minus SBC	CAD -98,981
Gross profit	CAD 523,043
Investing cash flow	CAD 44,850
Net borrowing	CAD 59,442
Net cash flow	CAD -11,548
Net income	CAD -656,339
Operating cash flow minus SBC	CAD -98,981
Operating income	CAD -574,039
Revenue	CAD 918,468
Stock-based compensation	CAD -16,859

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-299
Book value per share	CAD -0.05
Interest coverage	-2.12
Long-term assets	CAD 0
Long-term liabilities	CAD 0
Net cash (debt)	CAD -6M
Net cash / market cap	-907.01%
Piotroski F-Score	3
Shareholders' equity	CAD -6.9M
Tangible book value	CAD -6.9M
Tangible book value per share	CAD -0.05
Total assets	CAD 196,156
Total cash	CAD 13,860
Total debt	CAD 6M
Total liabilities	CAD 7.1M
WACC	3.47%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.74
Current assets	CAD 196,156
Current liabilities	CAD 7.1M
Current ratio	0.03
Inventory turnover	7.59
Net working capital	CAD -878,522
Quick ratio	0.03
Working capital	CAD -6.9M
Working capital turnover	-0.14

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.11%
10Y return CAGR	-37.61%
10Y total return	-99.11%
150-day SMA	CAD 0.02
1D price change	0%
1M price change	-50%
1M total return	-50%
1Y price change	-66.67%
1Y return CAGR	-66.69%
1Y total return	-66.67%
20-day SMA	CAD 0.01
200-day SMA	CAD 0.02
3Y price change	-93.33%
3Y return CAGR	-59.44%
3Y total return	-93.33%
50-day SMA	CAD 0.01
50-day SMA vs 200-day SMA	50under200
52-week high	CAD 0.04
52-week high date	2024-07-03
52-week low	CAD 0.01
52-week low date	2025-04-25
5Y price change	-94.74%
5Y return CAGR	-44.51%
5Y total return	-94.74%
6M price change	-50%
6M total return	-50%
All-time high	CAD 0.79
All-time high date	2015-03-26
All-time low	CAD 0.01
All-time low date	2024-11-11
Average true range (ATR)	CAD 0.00
Average volume	210.5K
Beta (1Y)	0
Beta (2Y)	-1.99
Beta (5Y)	-0.29
Change from 52-week high	-87.5%
Change from 52-week low	0%
Change from all-time high	-99.37%
Change from all-time low	0%
Monthly RSI	35.52
Previous close	CAD 0.01
Price vs 150-day SMA	-67.11%
Price vs 20-day SMA	-21.88%
Price vs 200-day SMA	-74.09%
Price vs 50-day SMA	-27.54%
Relative volume	0.48
RSI	45.19
Sharpe ratio	1.26
Sharpe ratio (3Y)	0.68
Sharpe ratio (5Y)	0.53
Sortino ratio	2.42
Sortino ratio (3Y)	1.27
Sortino ratio (5Y)	0.99
Volume	0
Weekly RSI	35.7
YTD price change	-50%
YTD total return	-50%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Shares change (QoQ)	0%
Shares held by insiders	15.78%
Shares outstanding	132.6M

Deeper analysis on TSXV/AQS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TSXV/AQS report

Is a complete TSXV/AQS research report available?

No complete published report is available for tsxv/AQS (TSXV/AQS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

TSXV/AQS (TSXV/AQS)

Price

Financial snapshot

Fair-value bridge

Latest news · TSXV/AQS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TSXV/AQS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Performance and technicals

Ownership and float

Deeper analysis on TSXV/AQS

Frequently asked questions